GBS Inc. (GBS) Research

Operating across North America and the Asia-Pacific region, GBS Inc. specializes in biosensor diagnostic technology. Its key product is the Saliva Glucose Biosensor, an innovative organic thin-film transistor designed for diabetes management that quantifies glucose levels directly from saliva. The company is also actively advancing a SARS-CoV-2 Biosensor, intended as a supplementary diagnostic tool to existing RNA virus detection tests, and is constructing a broad biosensor platform covering diagnostic modalities such as biochemistry, immunology, tumor markers, hormones, and nucleic acids. GBS Inc. maintains a research agreement with the Johns Hopkins Bloomberg School of Public Health for the development of saliva-based diagnostic solutions. Founded in 2016 and headquartered in New York, New York, the company adopted its current name, GBS Inc., in September 2019, having previously operated as Glucose Biosensor Systems (Greater China) Holdings, Inc. It operates as a subsidiary of Life Science Biosensor Diagnostics Pty Ltd.

Market snapshot

Symbol
GBS
Price
$0.47
Day change
-1.58%
Market cap
$1.5M
P/E ratio
-0.31x
52-week range
0.36-2.89
Sector
Healthcare
Industry
Medical - Devices

Peer companies

  • Biocept, Inc. (BIOC)
  • BIOLASE, Inc. (BIOL)
  • Leafly Holdings, Inc. (LFLY)
  • ProSomnus, Inc. (OSA)
  • Ontrak, Inc. (OTRK)
  • PAVmed Inc. (PAVM)
  • BiomX Inc. (PHGE)
  • Phio Pharmaceuticals Corp. (PHIO)

Recent insider activity

  • Sakiris Spiro Kevin — trade (0 shares) on 2023-10-04
  • TOWERS CHRISTOPHER — P-Purchase (9090 shares) on 2023-10-04
  • TOWERS CHRISTOPHER — P-Purchase (9090 shares) on 2023-10-04
  • TOWERS CHRISTOPHER — P-Purchase (9090 shares) on 2023-10-04
  • Sakiris Spiro Kevin — P-Purchase (112727 shares) on 2023-10-04

Open GBS Inc. (GBS) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.